Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of major adverse cardiovascular (CV) events and hospitalization for heart failure (HF) in patients with type 2 diabetes (T2D). Using CV MRI (CMR) and 31P-MRS in a longitudinal cohort study, we aimed to investigate the effects of the s...
שמור ב:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | אנגלית |
| יצא לאור: |
2021
|
| גישה מקוונת: | https://doi.org/10.2337/db21-0270 https://diabetesjournals.org/diabetes/article-pdf/70/12/2810/634595/db210270.pdf |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|